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Keypoints
 Complex factors inﬂuence the cell- or tissue-speciﬁcity of
vitamin D biological and growth effects, including local
synthesis, metabolism and transport of vitamin D and its
metabolites, vitamin D receptor (VDR) expression and ligand-
interactions, 1a,25-(OH)2 D3 genomic and non-genomic actions,
1a,25-(OH)2 D3-mediated Ca
2+ ﬂux, kinase activation, VDR
interactions with speciﬁc vitamin D responsive elements within
target gene promoters, VDR coregulator recruitment and
differential effects on key downstream target genes.
 Animal and in vitro studies show cell- or tissue-restricted
vitamin D growth control.
 Epidemiological studies indicate vitamin D tissue-speciﬁc effects
on neoplastic progression.
 E-cadherin and osteopontin (OPN) are functionally antagonistic
VDR target genes that orchestrate the growth response to 1a,25-
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A B S T R A C T
Substantive evidence implicates vitamin D receptor (VDR) or its natural ligand 1a,25-(OH)2 D3 in
modulation of tumor growth. However, both human and animal studies indicate tissue-speciﬁcity of
effect. Epidemiological studies show both inverse and direct relationships between serum 25(OH)D
levels and common solid cancers. VDR ablation affects carcinogen-induced tumorigenesis in a tissue-
speciﬁcmanner inmodel systems. Better understanding of the tissue-speciﬁcity of vitamin D-dependent
molecular networks may provide insight into selective growth control by the seco-steroid, 1a,25-(OH)2
D3. This commentary considers complex factors that may inﬂuence the cell- or tissue-speciﬁcity of
1a,25-(OH)2 D3/VDR growth effects, including local synthesis, metabolism and transport of vitamin D
and its metabolites, vitamin D receptor (VDR) expression and ligand-interactions, 1a,25-(OH)2 D3
genomic and non-genomic actions, Ca2+ ﬂux, kinase activation, VDR interactions with activating and
inhibitory vitamin D responsive elements (VDREs) within target gene promoters, VDR coregulator
recruitment and differential effects on key downstream growth regulatory genes. We highlight some
differences of VDR growth control relevant to colonic, esophageal, prostate, pancreatic and other cancers
and assess the potential for development of selective prevention or treatment strategies.
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 Consideration of 1a,25-(OH)2 D3-dependent signaling networks
in a cell-lineage or tissue-speciﬁc context may shed light on its
disparate growth regulatory effects and help exploit the
promising therapeutic potential of VDR ligands, for selected
cancers.
1. Introduction
1.1. The vitamin D endocrine system
Groundbreaking discoveries of the early 20th century eluci-
dated vitamin D’s essential role in calcium and phosphate
homeostasis, bonemineralization and enabledmajor public health
advances. The capacity of a novel fat-soluble vitamin that was
distinct from vitamins A, B or C, for prevention of experimentalicense.
Fig. 1. Chemistry of 1a,25-(OH)2 D3. 1a,25-(OH)2 D3 is derived from the 4
cyclopentanoperhydro-phenanthrene ring structure (A, B, C, and D rings) for
steroids. In 1a,25-(OH)2 D3, the 9,10 carbon–carbon bond of ring B is broken
between ring A and rings C and D (arrow, a) and the molecule is technically
classiﬁed as a seco-steroid. The molecule may then rotate along the bond between
ring A and rings C and D (arrow), to provide the structure of 1a,25-(OH)2 D3 (a).
Stepwise modiﬁcation of the molecule, involving location of a oxygen atom at
position 23 on the C and D ring side chain or removal of the terminal –OH group can
have important biological effects (b).
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Subsequently, Chick et al. demonstrated that clinical Rickets could
be cured by dietary cod liver oil supplementation or sunlight
exposure [2]. The Nobel prize in Chemistry was awarded to Dr
Adolf Windaus in 1928, in recognition of his achievement in
isolation of vitamin D and demonstration of its steroid structure
[3]. In the 1930s, fortiﬁcation of milk with vitamin D virtually
eradicated Rickets from the United States, although it had
previously been a highly prevalent crippling disease of childhood
[4].
The mammalian form of vitamin D is a fat-soluble prohor-
mone cholecalciferol (vitamin D3) that may be generated
endogenously by ultraviolet light-mediated metabolism of the
precursor sterol 7-dehydrocholesterol, in the skin. Alternatively,
vitamin D3 may be obtained from dietary sources [5]. This
prohormone (cholecalciferol) is hydroxylated to 25-hydroxy-
cholecalciferol (25(OH)D3) by hepatocyte 25-hydroxylase.
Further hydroxylation by 1a-hydroxylase (CYP27B1), into the
main biologically active hormone, 1a 25-dihydroxycholecalci-
ferol (1a,25-(OH)2 D3 or calcitriol) occurs in the proximal renal
tubule in a tightly regulated fashion [6]. 1a,25-(OH)2 D3 then
acts as a steroid chemical messenger in a diverse target tissues,
in what is known as the vitamin D endocrine system [7]. To meet
needs of bone mineralization, 1a,25-(OH)2 D3 stimulates
intestinal calcium and phosphate absorption, bone calcium
and phosphate metabolism as well as renal calcium and
phosphate reabsorption, by differential effects on osteoblasts,
chondrocytes, renal and intestinal epithelia [8]. Furthermore,
discovery of VDR expression in diverse normal human tissues
including B and T lymphocytes, the hair follicle, muscle, adipose
tissue, bone marrow and in cancer cells has widened the
perceived scope of the vitamin D endocrine system, beyond bone
homeostasis [7].
1.2. 1a,25-(OH)2 D3 chemical structure and conformational
relationships
1a,25-(OH)2 D3, the active form of vitamin D, is a highly ﬂexible
molecule with a steroid carbon skeleton, involving 4 fused
cyclopentanoperhydro-phenanthrene rings, A–D. Unlike other
steroids, the 9–10 carbon bond is broken, thus creating a
conformationally ﬂexible molecule in which the ‘‘A’’ ring may
rotate (Fig. 1). The molecule is technically classiﬁed as a seco-
steroid. The spatial arrangements of principal functional compo-
nents of the 1a,25-(OH)2 D3molecule comprise a hugely important
determinant of its biological activities. Cis–trans isomerism
inﬂuences stability and reactivity. The unusual degree of ﬂexibility
within 1a,25-(OH)2 D3 enables synthesis of structural analogs
(Fig. 1b) that elicit well-deﬁned subsets of the vitamin D response
(see below) [9,10].
1.3. Vitamin D transport
Normally, only 0.04% of 25(OH)D and 0.4% of 1a,25-(OH)2 D3
are free in plasma, the remainder being tightly bound to either a
vitamin D transporter protein (DBP) (85–88%; high afﬁnity;
dissociation constant [Kd]  1 nM) [11] or albumin (12–15%; low
afﬁnity) [12]. Only free unbound vitamin D sterols are considered
to be biologically active, since only the free form and not DBP-
bound 1a,25-(OH)2 D3 induces metabolic responses in target
cells [13]. In addition to transport, DBP functions to maintain
stable serum stores of vitamin D metabolites, modulate
bioavailability and inﬂuence responsiveness of some end-organs
[14]. 1a,25-(OH)2 D3 binds to its ‘‘nuclear’’ receptor (VDR) with
high afﬁnity (dissociation constant value of [Kd]  1 nM or lower)
[15].1.4. The vitamin D receptor (VDR)
Free 1a,25-(OH)2 D3 enters the cell and binds the vitamin D
receptor (VDR) (Fig. 2a), that may be present in the cytoplasm,
nucleus or partitioned between the cytoplasm and nucleus [16].
VDR is an endocrine member of the nuclear receptor superfamily
[8] with high structural and ligand-binding homology across
various species [6]. Ligands for VDR include bile acidmetabolites as
well as 1a,25-(OH)2 D3 [17]. VDR has the same modular structure
as othermembers of the nuclear receptor superfamily, including an
N-terminal A/B region, a conserved DNA-binding domain, a ﬂexible
hinge region and a moderately conserved ligand-binding pocket
that contains a dimerization interface and a ligand-dependent
transcriptional activation domain, AF-2 [18] (Fig. 2a and b). Ligand
binding induces a conformational change of the AF-2 region that
allows dissociation of accessory proteins, exposure of the DNA-
binding pocket and recruitment of coactivators [19]. Speciﬁc
mutations that cause deletions, frameshift mutations, premature
stop codons or splice site abnormalities that impede VDR
expression or binding activity, effectively suppress key VDR
actions [20].
1.5. 1a,25-(OH)2 D3/VDR mediated genomic responses
The 1a,25-(OH)2 D3/VDR complex functions to regulate gene
transcription through heterodimerization with any of three
retinoid X receptor (RXR) isoforms and binds to cognate vitamin
D responsive elements (VDREs) in the promoter region of target
genes. VDRE structures within promoter regions of primary 1a,25-
(OH)2 D3 regulated genes can vary [21]. However, the majority of
known VDREs show a DR3-type structure comprising a directly
repeated arrangement of hexameric binding sites with 3 spacing
nucleotides [22]. This arrangement provides the most efﬁcient
interface for VDR/RXR heterodimer binding to core VDREs.
Subclasses of DR3 VDREs show some sequence variation but their
in vivo functionality is proportional to their in vitro binding afﬁnity
Fig. 2. Schematic representation of the vitamin D receptor (VDR) domain structure. (a) VDR protein backbone and 1a,25-(OH)2 D3 ligand-binding pocket. The VDR protein
backbone is represented by a ribbon. A space-ﬁlling representation of 1a,25-(OH)2 D3 is shown within the VDR ligand-binding pocket by an atom-based structure.
Conformational modiﬁcation of the vitamin D side chain may inﬂuence ligand binding and transcriptional activity [125]. (b) The human VDR gene domain structure. The
human VDR gene is composed of 9 exons that encode domains (A–F). Upon 1a,25(OH)2 D3 binding to the hormone ligand-binding domain, VDR is stabilized by the
phosphorylation of serine 51 in the DNA-binding domain and serine 208 in the hinge region. VDR associates with the retinoic acid receptor (RXR) through the dimerization
domains in E/F. The 1a,25-(OH)2 D3–VDR–RXR complex binds to the vitamin D response elements (VDREs) through the DNA-binding domain in the promoters of target genes.
Conformational change in VDR results in co-repressor dissociation and enables interaction of the AF2 transactivation domain with stimulatory coactivators, such as steroid
receptor coactivators (SRCs), vitamin D receptor-interacting proteins complex and nuclear coactivators.
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observed among class I DR3-type VDREs, including that present
in the osteopontin (OPN) promoter [23]. 1a,25-(OH)2 D3 may
regulate genes that do not contain VDREs within their promoter
regions, through non-genomic VDR actions (see below).
1.6. VDR/VDRE mediated coactivation or corepression of gene
transcription
Regulation of gene expression by 1a,25-(OH)2 D3 genomic
signaling, is dependent upon the ability of VDR/RXR heterodimers
to recruit coregulatory protein complexes [24] thatmay activate or
repress target gene expression. Ligand triggered conformational
change of VDR–RXR heterodimers results in dissociation of co-
repressor proteins such as NCoR (nuclear receptor co-repressor)
and facilitates the interaction with members of the CBP/p300 and
p160 coactivator families including SRC-1 (steroid receptor
coactivators-1), TIF2 (transcriptional intermediary factor 2), and
RAC3 (receptor activated coactivators 3) [25]. DRIP (vitamin D
receptor-interacting protein) cofactor complexes are also involved
in parallel [19]. These coactivators bind ligand-activated VDR,
induce a coactivator exchange in the transcriptional complex of
VDR-responsive promoters [26] and enables opening of thechromatin structure. These effects create an environment suitable
for gene transcription [27].
VDR may also repress gene transcription. CYP27B1 catalyzes
the metabolic activation of 1a,25-(OH)2 D3 from its precursor [28]
and is negatively regulated by 1a,25-(OH)2 D3, in a cell-lineage-
speciﬁc and tissue-restricted manner [29]. CYP27B1 and other
genes including PTH [30] are thought to be suppressed by 1a,25-
(OH)2 D3 via negative vitamin D response elements (VDREs).
Ligand-activated VDR binds to the 5’ half site of negative VDREs
[30]. VDR–RXR heterodimers interact with a VDR-interacting
repressor (VDIR) at the E-box type element of negative VDREs,
comprising a CANNTG-like motif. Such interactions at the E-box
induce coregulator switching, involving dissociation of p300
coactivators but association of the histone deacetylator (HDAC)
co-repressor complex, resulting in ligand-induced transrepression.
Cell or tissue-speciﬁc transrepression of CYP27B1 by 1a,25-(OH)2
D3 may involve multiple VDREs located in more distal promoter
regions that enhance chromatin looping and interactions with
protein super complexes of differing transcriptional abilities. Other
mechanisms of transrepression involve the association between
WINAC (Williams syndrome transcription factor (WSTF) including
nucleosome assembly complex), a multifunctional, ATP-depen-
dent chromatin-remodelling complex and chromatin [31] and
Fig. 3. Transcriptional regulationbyvitaminD.Classicalactionof1a,25-(OH)2D3 ismediatedbybindingof theVDR/RXRcomplexatVDREs. (a) Transcriptionalactivation involves
the co-activator molecules SRCs, NCoA62, HATs, CBP p300 and other molecules to derepress chromatin. (b) Binding of DRIP to the AF2 domain attracts a complex containing
transcription factor 2B (TF2B) andRNApolymerase II (RNAPol II) for transcription initiation. The presence of themultiprotein complex facilitates increasedgene transcription. (c)
1a,25(OH)2 D3-mediated transcriptional repression involves VDR–RXR heterodimer association with VDR-interacting repressor (VDIR) bound to E-box-type negative VDREs
(nVDREs), dissociation of the HAT co-activator and recruitment of histone deacetylase (HDAC) co-repressor. Williams syndrome transcription factor (WSTF) potentiates
transrepression by interacting with a multifunctional, ATP-dependent chromatin-remodelling complex (WINAC) and chromatin. This leads to the repression of genes, such as
CYP27B1 (whichencodes1a-OHase)andPTH (whichencodesparathyroidhormone). (d)Non-genomic, rapidactionsof1a,25-(OH)2D3arethoughactivationofmitogen-activated
proteinkinase (MAPK)–extracellular signal-regulatedkinase (ERK)1 and2 cascade through thephosphorylation (P) andactivationofRaf byproteinkinaseC (PKC), partly through
induced changes of intra-cellular Ca2+ concentration (reproduced from Deeb et al. [126] with kind permission of Dr CS Johnston Roswell Park CI, New York and the publisher).
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classical 1a,25-(OH)2 D3 genomic response modulate synthesis
and accumulation of new proteins and invoke appropriate cellular
responses, over intervals of hours or days. These eventsmay also be
suppressed by protein synthesis inhibitors, such as actinomycin D
or cycloheximide [16].
1.7. 1a,25-(OH)2 D3-mediated rapid or non-genomic responses
Notwithstanding the strong, non-covalent binding of 1a,25-
(OH)2D3 to its cognate receptor, this active sterol can alsoelicit rapid
responses in target cells of the vitamin D endocrine system. Effects
include generation of calcium or ion ﬂux [33], induction of second
messenger systems [34] and activation of cytosolic kinases [35].
1a,25-(OH)2 D3 may promote rapid Ca
2+ inﬂux from the extra-
cellular space through voltage-independent channels in rat osteo-
sarcoma cells [36], release Ca2+ from intra-cellular stores in
osteoblasts [37] and activate protein kinase pathways that may
be Ca2+-dependent or -independent [37,38]. These effects occurrapidly within minutes and are considered incompatible with
mechanisms involving alterations in gene transcription and protein
synthesis [33]. Involvement of VDR in this pathway remains
controversial, since rapid actions of 1a,25-(OH)2 D3may be invoked
in cells that lack VDR [39]. However, in various cell types rapid
responses can be mediated by 1a,25-(OH)2 D3 acting through a
population of classical VDR molecules acting outside the cell
nucleus, associated with caveolae of the plasma membrane [40].
Importantly, analogs of different vitamin D isomers that are
locked in cis- or trans-conformations have been synthesized which
can preferentially elicit rapid non-genomic and/or genomic
responses [9,10].
1.8. 1a,25-(OH)2 D3 dual regulation of gene expression by genomic
and rapid non-genomic pathways
There is compelling evidence that the rapid non-genomic
activation of signal transduction pathways by 1a,25-(OH)2 D3 can
interact with and modulate VDR-dependent gene transcription
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complex selectively recognizes VDREs in the promoter regions of
osteopontin (OPN) [43] and osteocalcin (OCN) [44] genes, the
steady state levels of OPN and OCN mRNA can also be modulated
by 1a,25-(OH)2 D3 rapid non-genomic actions [45]. Furthermore,
antagonism of the non-genomic pathway blocks 1a,25-(OH)2 D3-
mediated OCN expression [41]. 1a,25-(OH)2 D3 rapid activation of
cytosolic kinases may phosphorylate critical coactivators resulting
in modulation of VDR-dependent gene transcription [46]. By non-
genomic actions, 1a,25-(OH)2 D3 can modulate a repertoire of
cytosolic kinases and second messenger systems that show some
level of cell- or tissue-speciﬁcity [38], e.g. activation of phospho-
lipase A2 in chondrocytes [47] and protein kinase A in enterocytes
[48]. By cross-talk with VDR/VDRE regulation of gene transcrip-
tion, these membrane-mediated kinase cascades may inﬂuence
cell-speciﬁc biological responses to 1a,25-(OH)2 D3, involved
diverse physiological and pathobiological processes [7].
1.9. Tissue- and cell-speciﬁcity of vitamin D biological effects
Most tissues express the receptor for 1a,25-(OH)2 D3 (VDR)
and renal tubules, skin, bone, brain, breast, colon and prostate
also contain the enzyme CYP27B1, required for converting the
major circulating metabolite of vitamin D, [25(OH)D] to 1a,25-
(OH)2 D3 [49]. Notwithstanding the wide distribution of VDR and
CYP27B1, 1a,25-(OH)2 D3 shows highly tissue-speciﬁc functional
effects on hormone secretion, immune function, cell differentia-
tion and growth. For example, 1a,25-(OH)2 D3 inhibits PTH
secretion in the parathyroid glands [30] but stimulates pan-
creatic b-cell insulin secretion [50], inhibits adaptive immunity
[51] but enhances some innate immune responses [52], inhibits
differentiation of B lymphocytes [53] but enhances keratinocyte
differentiation [54].
1a,25-(OH)2 D3-mediated growth effects may show similar
cell-speciﬁcity. For example, 1a,25-(OH)2 D3 has antiproliferative
effects in some neoplastic cells [55] but induces a spectrum of
growth responses in others. The PC-3 and DU-145 prostate cancer
cell lines for example are not signiﬁcantly inhibited by physio-
logically relevant doses of 1a,25-(OH)2 D3 [56]. Furthermore, at
low or physiological concentrations, 1a,25-(OH)2 D3 may promote
proliferation of monocytes [57] or keratinocytes [58]. Effects upon
anchorage-independent growth and invasion may show similar
cell-speciﬁcity. For example, 1a,25-(OH)2 D3 or analogs inhibited
anchorage-independent growth of prostate cancer cells [59] and
suppressed invasion through Matrigel by these cells [59] and
neuroblastoma cells [60]. Conversely, vitamin D or analogs may
also enhance anchorage-independent growth [61] and promote
12-O-tetradecanoylphorbol-13-acetate (TPA) induced neoplastic
transformation in JB6 epidermal cells [62].
These observations do not support uniform growth or other
biological responses to vitamin D exposure. Rather, cell- or tissue-
speciﬁc processes, could modulate the initiating 1a,25-(OH)2 D3
signal to provide different functional outcomes.
2. The Yin and Yang of 1a,25-(OH)2 D3 growth regulatory
signaling
Expression proﬁling has identiﬁed diverse targets of 1a,25-
(OH)2 D3 non-genomic or genomic actions including G-coupled
receptors, inter- and intra-cellular signaling genes, cell-cycle
regulators, metabolic function moeties, extracellular matrix
components and cell adhesion molecules [63]. From within these
networks, 1a,25-(OH)2 D3 not only regulates bone mineralization
but also modulates growth and differentiation [64]. Such diversity
of biological effect could be achieved in part through genomic/non-
genomic cross-talk, molecular networks or transcriptomes impli-cated in lineage specialization or effects on target genes with
context-speciﬁc functions.
Within such modular networks, osteopontin (OPN) and E-
cadherin play important roles in growth responses to vitamin D
[65,66]. Osteopontin (OPN) is a key vitamin D target gene,
regulated by 1a,25-(OH)2 D3-mediated genomic [26] and non-
genomic mechanisms [45,67]. OPN is an extracellular matrix
glycophosphoprotein implicated in osteoblast differentiation [45]
but is also a central effector of vitamin D – mediated anchorage-
independent growth [68]. OPN may abrogate the adhesion
requirement for cell growth and enhance cell invasion through
Matrigel by activation of Ran GTPase (RAN) [69]. 1a,25-(OH)2 D3
transcriptional regulation of OPN involves VDR/RXR heterodimer
binding and recruitment of coregulators including SRC-1, -2, -3,
CBP, p300 and DRIP205 to VDREs within the OPN promoter [26].
Mutation at one or both VDRE sites in the rat OPN promoter
substantively suppresses 1a,25-(OH)2 D3-mediated transcription
of a OPN-promoter luciferase reporter construct [70]. However,
OPN mRNA may also be activated by VDR non-genomic actions,
involving Ca2+-inﬂux and rapid activation of the small GTPAse,
RhoA and its effector, Rho-associated coiled kinase (ROCK) [67].
Effects of this non-genomic pathway on OPN protein expression
are unclear [67]. RhoA–ROCK activation of OPN mRNA in smooth
muscle cells is Erk dependent andmay be suppressed by the MEK1
inhibitor, PD98059 [71].
E-cadherin is induced by 1a,25-(OH)2 D3 non-genomic rapid
actions [67] and suppresses cell growth, partly by inhibition of b-
catenin transcriptional activity [72,73]. Free b-catenin that is
sequestered by E-cadherin, is rapidly phosphorylated by glycogen
synthase kinase3b (GSK3b) in the adenomatous polyposis coli
(APC)/axin/GSK-3b/casein kinase I complex and is subsequently
ubiquitinated and degraded. Loss of this function enables b-
catenin accumulation and translocation to the nucleus where it
modulates the expression of Tcf/Lef-1-target genes implicated in
cell proliferation [74]. 1a,25-(OH)2 D3 induction of E-cadherin
involves transcription-independent promotion of Ca2+-inﬂux and
consequent activation of RhoA–ROCK signaling. Subsequent to
these events, induction of p38/MAPK-MSK1 signaling upregulates
E-cadherin and inhibits b-catenin/Tcf transcriptional activity [67].
Hence, OPN and E-cadherin are functionally antagonistic growth
regulatory genes that are modulated by 1a,25-(OH)2 D3 through
overlapping but distinct molecular mechanisms.
2.1. Growth signaling through E-cadherin and OPN: functional
outcomes of 1a,25-(OH)2 D3 treatment
E-cadherin and OPN are reciprocally regulated through b-
catenin/Tcf and related signaling pathways [75] to provide high
and low levels respectively, in quiescent normal tissue [76,77].
Disturbance of this equilibrium in early stages of multistep
tumorigenesis may have phenotypic effects on cell adhesion [78],
migration [76] and invasion [68]. Aberrant expression of these
genes in early tumorigenesis may inﬂuence the subsequent
development of abnormal molecular circuitry in evolving cancer
cells.
To investigate involvement of the E-cadherin/OPN equilibrium
in 1a,25-(OH)2 D3 growth control, Xu et al. used parental cell lines
and stably transformed subclones with variable constitutive
expression of these genes [70]. Parental R37 mammary cells
highly express E-cadherin, have an epithelial-like morphology,
have low levels of Tcf-1 indicative of low level b-catenin signaling
activity and weak expression of OPN. Subclones were raised by
stable transfection of R37 cells with metastatic tumor DNA
fragments (R37 Met-DNA; [C9] cells) that upregulates OPN [79].
Subclones were also raised by transfection of parental R37 cells
with OPN cDNA in sense or antisense orientations respectively, in
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OPN and Tcf-1, low levels of E-cadherin, have a spindle-like
morphology and are invasive [75]. In these cells, OPN is considered
to be the direct effector of Met-DNA, in promotion of invasion or
metastasis [80]. In thismodel system, 1a,25-(OH)2 D3 and novel A-
ring modiﬁed vitamin D analogs inﬂuenced the balance of these
antagonistic VDR-dependent signals. All treatments upregulated
E-cadherin, suppressed b-catenin transcriptional activity and b-
catenin nuclear localization, consistent with growth-inhibition.
However, all treatments also upregulated OPN that may be
implicated in neoplastic transformation and invasion.
Although molecular cross-talk was observed, growth effects
induced by 1a,25-(OH)2 D3 or analogs appeared dependent upon
the constitutive balance of these functionally antagonistic
molecules, in target cells. VDR ligands signiﬁcantly increased
migration or invasion only in those cells with high constitutive
OPN and low E-cadherin [70]. This ﬁnding suggests that the pre-
treatment activity state of antagonistic VDR-dependent molecules
may inﬂuence cell-speciﬁc 1a,25-(OH)2 D3 growth responses.
These fundamental studies may provide greater understanding of
1a,25-(OH)2 D3 growth effects relating to cancer, in whole animal
studies as well as clinical or epidemiological surveys.
2.2. Tumorigenesis in VDR knockout mice
Development of a nullmousemodel has provided an important
tool for study of 1a,25-(OH)2 D3/VDR functional roles in tumor
biology. VDR null mice appear developmentally normal at birth
but manifest growth abnormalities, alopecia and infertility from
the timeofweaning [81].Mice deﬁcient inVDRor key components
of the vitamin D synthetic pathway do not manifest any increase
of sporadic tumorigenesis [82]. However, VDR ablation alters
susceptibility to chemically induced carcinogenesis in a tissue-
speciﬁc manner [83]. Administration of DMBA together with
medroxprogesterone induced increased formation of skin tumors
andmammary hyperplasia in VDR knockout vs. control mice [83].
Although differences were observed in development of thymic
lymphomas, lymphoblastic leukemias and mammary tumor
histopathology, VDR status did not affect overall non-epidermal
tumor incidence. No effects were observed on tumorigenesis in
the ovary, uterus, liver or lung, despite expression of the VDR in
these tissues. These ﬁndings provide strong evidence that VDR
signaling alters chemically induced carcinogenesis in a manner
that is tissue-speciﬁc but unrelated to VDR expression, in vivo
[83].
2.3. Vitamin D exposures and human cancer risk
Associations between sunlight exposure, dietary histories and
tumor incidence in various epidemiological surveys imply an
important role for vitamin D in lifetime cancer risk and/or survival
[84]. For example, mortality from colon cancer was found to be
higher in geographical regions of the United States with low
sunlight exposure [85] while decreased colon [86], breast [87] and
prostate cancer risk [88] were reported in high sunlight areas.
Inverse relationships between dietary vitamin D intake and breast
cancer have been reported [89,90] although ﬁndings for colorectal
cancer appeared inconsistent [91,92] and no clear associations
were found for prostate cancer [93,94]. The relationship between
sunlight exposure and risk of lymphoma has also been con-
troversial. Studies have shown positive [95,96], inconsistent [97]
or inverse [98] relationships between estimated solar ultraviolet
exposure and non-Hodgkins lymphoma (NHL). No clear associa-
tion between dietary intake of vitamin D and risk of NHL, diffuse
large B-cell lymohoma, chronic lymphocytic leukemia or follicular
lymphoma were found [99]. Study participants’ histories of sunexposure or intake of foods that are high in vitaminDmay however
be subject to systematic recall error and associated bias.
The vitamin D metabolite 25-OHD has a long half-life and
serum levels may provide a robust biomarker of vitamin D status
[100]. Subjects with high levels of 25-OHD were found to have a
lower incidence of colorectal cancer (CRC), in both women and
men [101,102], Freedman and colleagues conﬁrmed an inverse
association between serum 25-OHD levels and CRC risk and
demonstrated that the highest percentile serum 25-OHD levels
had a CRC relative risk (RR) of 0.28 [103]. No clear association with
total cancer mortality was observed, however [103]. Associations
between 25-OHD levels, breast [104,105] and total prostate cancer
[106–108] have been inconsistent. In a nested case–control study
involving 270 incident lymphoid cancer cases and 538 controls
from a cohort of 29,133 Finnish male smokers, serum 25-OHD
levels were not associated with the risk of overall lymphoid
cancers, NHL or multiple myeloma [109]. However, high serum
serum 25-OHD levels were associated with increased risk of
pancreatic cancer in 200 Finnish cases and 400 controls, from this
same total cohort [110]. In a further nested case–control study,
high prediagnostic serum 25-OHD levels had increased risk of
aggressive prostate cancer in 749 cases and 781 control subjects
from the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Trial [108].
In the nested case–control study design, non-diseased subjects
from whom the controls are selected may not be fully representa-
tive of the healthy population [111]. In a prospective cohort study
of >700 apparently healthy adults from the Linxian region of
China, higher serum 25(OH)D concentrationswere associatedwith
signiﬁcantly increased risk of development of esophageal squa-
mous dysplasia [112] and invasive squamous carcinoma [113].
These epidemiological studies show positive and negative
associations between vitamin D status and common solid cancers
in various populations and allude to tissue-speciﬁcity of effect. At
present, any chemopreventive beneﬁts of higher serum 25(OH)D
levels for colorectal cancer [102,103] may require to be weighed
against potential increased risks of esophageal squamous dysplasia
[112] or cancer [113], pancreatic cancer [110] or aggressive
prostate cancer [108]. Within interacting molecular networks that
inﬂuence tissue-speciﬁc responses to 1a,25-(OH)2 D3, a dynamic
equilibrium of positive or negative growth signals may determine
ultimate outcomes, although key molecules can have speciﬁc
effects upon development of neoplastic phenotype.
2.4. Tissue-speciﬁc VDR operational networks and cancer risk
The VDR growth regulatory equilibrium involving E-cadherin
and OPN is disturbed during stepwise evolution of many human
cancers [77,114] although there are important tissue-speciﬁc
differences. In the colon for example, adenomatous polyps
represent the commonest identiﬁable premalignant lesion. These
colonic adenomas have E-cadherin/OPN expression patterns
resembling that of normal mucosa, namely preservation of E-
cadherin [115] and lowor undetectableOPN [116].Hence, in these
lesions, high level serum [25(OH)D] could further increase E-
cadherin tumor suppressor activity, set against low level OPN
with an overall effect of growth restraint. By this rationale,
persistently high serum [25(OH)D] could impede neoplastic
progression of colonic adenomas which are common in asympto-
matic Western populations [117], with ultimate reduction of CRC
incidence. Conversely, preneoplastic squamous mucosal hyper-
plasia or dysplasia are common in high risk areas for esophageal
cancer [118]. Unlike colonic adenomas, these lesions are
characterised by early suppression of E-cadherin [119] and
upregulation of OPN [120]. In such populations, higher serum
[25(OH)D] levels are associated with increased esophageal
F.C. Campbell et al. / Biochemical Pharmacology 79 (2010) 1–9 7squamous cancer risk [113]. Potentially, high 1a,25-(OH)2 D3
exposure could enhance the predominance of OPN growth-
promoting signals and associated Ran activity [69] in these
lesions, beyond the threshold level required for invasion and
neoplastic progression. Neoplasms of the pancreas and prostate
are characterised by similar disequilibrium involving low E-
cadherin and high OPN [121–124] which could potentially be
related to the direct associations between serum [25(OH)D] levels
and risks of pancreatic cancer or aggressive prostate cancer
[67,108,110].
Tissue-speciﬁc 1a,25-(OH)2 D3 growth responses may involve
complex non-genomic/genomic cross-talk and modulation of
downstream signals by distinct lineage-speciﬁc expression pat-
terns of the human transcriptome. However, the E-cadherin/OPN
expression balance may provide a useful biologically based
marker of this complexity, implicated in 1a,25-(OH)2 D3 growth
responses.
2.5. Towards conditional targeting strategies
The above studies address fundamental mechanisms and link
tissue-speciﬁc differences of VDR growth regulatory networks,
particularly involving OPN and E-cadherin to epidemiological
associations between serum [25(OH)D] levels and cancer.
Although genomic effects of 1a,25-(OH)2 D3 are partly
implicated in induction of OPN [7], they appear dispensible for
induction of E-cadherin in colorectal cells [67]. 1a,25-(OH)2 D3
induces transcription-independent Ca2+ inﬂux and activation of
RhoA-ROCK, in the presence VDR. Thus activated, RhoA-ROCK
upregulates p38MAPK andMSK1, leading to substantive induction
of E-cadherin mRNA and protein, inhibition of b-catenin/Tcf
transcriptional activity and suppression of cell proliferation [67].
OPN mRNA may also be regulated by 1a,25-(OH)2 D3 through
transcription-independent, Ca2+-dependent RhoA/ROCK activation
although the response appears less robust than that of E-cadherin.
1a,25-(OH)2 D3 induced 30-fold induction of E-cadherinmRNAbut
less than 10-fold upregulation of OPN mRNA within 8 h [67].
Downstream of Rho/ROCK, p38/MSK1 is required for induction of
E-cadherin [67]. Conversely, in smooth muscle cells RhoA/ROCK
activation of ERK is implicated in upregulation of OPN mRNA.
Additional work is required to explore mechanistic issues
involving 1a,25-(OH)2 D3 rapid vs. genomic effects, regulation of
signaling kinases and differential activation of E-cadherin/OPN
growth regulatory genes. Rational design of combination therapies
that allows activation of E-cadherin without upregulation of OPN
may be a useful target for tissue-speciﬁc pharmacotherapeutics,
particularly for preneoplastic states characterised by high con-
stitutive OPN. Such future advances may provide a rationale for
improved prevention and treatment of different cancers, through
VDR mediated growth control.
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